STOCK TITAN

22nd Century Group to Participate in the Planet MicroCap Showcase on May 1-2, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
22nd Century Group, Inc. (XXII) will participate in the Planet MicroCap Showcase on May 1-2, 2024, presenting at 3:30 PM Pacific Time. Investors can access the live presentation via webcast. The company will also host individual investor meetings on May 2, 2024, at the Paris Hotel & Casino in Las Vegas, NV.
Positive
  • None.
Negative
  • None.

Mocksville, North Carolina--(Newsfile Corp. - April 15, 2024) - 22nd Century Group, Inc. (NASDAQ: XXII), a tobacco products company focused on nicotine harm reduction, today announced that it will present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 at 3:30 PM Pacific Time.

To access the live presentation, please use the following information:
Date: Wednesday, May 1, 2024
Time: 3:30 PM Pacific Time
Webcast: https://ir.xxiicentury.com/

Management will also host individual investor meetings on Thursday, May 2, 2024, as part of its participation in the conference. Investors can register online at https://planetmicrocapshowcase.com/signup and request a meeting time with the Company. Meetings will be scheduled and conducted in person at the conference venue, Paris Hotel & Casino in Las Vegas, NV.

The Planet MicroCap Showcase: VEGAS 2024 website is available here: https://planetmicrocapshowcase.com/

If you can't make the live presentation, all company presentations "webcasts" will be available directly on the conference event platform on this link under the tab "Agenda": https://planetmicrocapshowcase.com/agenda.

About 22nd Century Group, Inc.
22nd Century Group, Inc. (NASDAQ: XXII) is an agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the FDA's Comprehensive Plan to address the widespread death and disease caused by smoking. The Company received the first and only FDA Modified Risk Tobacco Product (MRTP) authorization for a combustible cigarette in December 2021. 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits.

Learn more at xxiicentury.com, on Twitter, on LinkedIn, and on YouTube.

Learn more about VLN® at tryvln.com.

Cautionary Note Regarding Forward-Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-Looking statements typically contain terms such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "explore," "foresee," "goal," "guidance," "intend," "likely," "may," "plan," "potential," "predict," "preliminary," "probable," "project," "promising," "seek," "should," "will," "would," and similar expressions. Forward-Looking statements include, but are not limited to, statements regarding (i) our strategic alternatives and cost reduction initiatives, (ii) our expectations regarding regulatory enforcement, including our ability to receive an exemption from new regulations, (iii) our financial and operating performance and (iv) our expectations for our business interruption insurance claim. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in "Risk Factors" in the Company's Annual Report on Form 10-K filed on March 28, 2024. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact
Matt Kreps
Investor Relations
22nd Century Group
mkreps@xxiicentury.com
214-597-8200

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/205502

FAQ

When will 22nd Century Group participate in the Planet MicroCap Showcase?

22nd Century Group will participate in the Planet MicroCap Showcase on May 1-2, 2024.

What time will 22nd Century Group present at the showcase?

22nd Century Group will present at 3:30 PM Pacific Time on May 1, 2024.

Where will the live presentation be accessible?

The live presentation can be accessed via webcast at https://ir.xxiicentury.com/ on May 1, 2024.

Where will the individual investor meetings take place?

The individual investor meetings will take place at the Paris Hotel & Casino in Las Vegas, NV on May 2, 2024.

How can investors register for individual meetings with 22nd Century Group?

Investors can register online at https://planetmicrocapshowcase.com/signup and request a meeting time with the Company.

22nd Century Group Inc.

NASDAQ:XXII

XXII Rankings

XXII Latest News

XXII Stock Data

9.25M
3.28M
0.65%
6.58%
5.51%
Tobacco Manufacturing
Manufacturing
Link
United States of America
WILLIAMSVILLE

About XXII

with the mission of reducing the harm caused by smoking, 22nd century is a plant biotechnology company whose proprietary technology allows for the levels of nicotine in the tobacco plant to be decreased or increased through genetic engineering and plant breeding. goodrich tobacco company and hercules pharmaceuticals are wholly-owned subsidiaries focusing on (i) premium cigarettes and potentially reduced risk tobacco products (with up to 97% less nicotine than conventional cigarettes), and (ii) the x-22 prescription smoking cessation aid in development. 22nd century's technology also allows the levels of cannabinoids to be decreased or increased in the cannabis plant.